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Abstract
Background: The benefit of statins for prevention of cardiovascular events in type 2 diabetes is
established, but a gap exists between guideline recommendations and clinical practice. The aim of
the study was to identify patient-related factors predicting statin prescription.
Methods: We assessed the quality of care in 51,640 patients with type 2 diabetes in a German
diabetes registry. Patients were stratified according to primary and secondary prevention. Five-year
risk for cardiovascular events was calculated in primary prevention patients. A multivariate adjusted
logistic regression model was constructed to determine which parameters influenced statin
prescription.
Results: 34% had established atherosclerotic disease and 25.5% received a statin. Prescription was
significantly higher in the secondary compared to the primary prevention group (38.1% [95% CI
37.4–38.9%] vs. 18.5% [95% CI 18.0–19.0%], respectively). In primary prevention the odds for statin
prescription increased with estimated cardiovascular risk (OR 1.17 per 5% increase in 5-year risk,
95% CI 1.11–1.22). Positive predictors for statin prescription were secondary prevention,
hypertension, former smoking, baseline LDL-cholesterol, and microalbuminuria. The odds of
receiving a statin had an inverted U-shaped relation with age (nadir, 66 years), age at first diagnosis
of diabetes (nadir, 56 years), and body mass index (nadir, 32 kg/m2). The model predicted
prescription in 70% of the patients correctly.
Conclusion:  The majority of patients with type 2 diabetes are not receiving statins. The
predominant factors determining statin prescription are the patient's prevention status and, in
primary prevention, estimated cardiovascular risk. The results suggest that although physicians are
aware of the general concept of cardiovascular risk, they fail to consistently implement guidelines.
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Background
Patients with diabetes have a substantially increased risk
of atherosclerotic vascular disease [1]. A recent meta-anal-
ysis examined whether statins (HMG-CoA reductase
inhibitors) are as beneficial in preventing cardiovascular
events in patients with diabetes as they are in those with-
out, and found that in patients with diabetes there was a
9% proportional reduction in all-cause mortality per
mmol/l (~40 mg/dl) reduction on LDL cholesterol, a
reduction similar to the 13% reduction seen in patients
without the disease [2]. There were significant reductions
in the numbers of fatal and non-fatal myocardial infarc-
tions, coronary revascularisations, and strokes. Moreover,
the relative risk reduction was independent of previous
history of vascular disease and of baseline subject charac-
teristics.
Current type 2 diabetes guidelines issued by European
and American scientific societies recommend lipid-lower-
ing treatment with statins in order to reach the LDL-C tar-
get levels of < 100 mg/dl or of < 70 mg/dl in individuals
with coexisting cardiovascular disease (CVD) [3-5]. How-
ever, studies suggest that large discrepancies exist between
treatment targets and clinical reality. We have recently
shown that the proportion of patients with type 2 diabetes
in Germany receiving a statin is low, namely only 25%
[6]. Moreover, only about 6% of these patients reach all
three lipoprotein targets (LDL-C < 100 mg/dl, triglycerides
< 150 mg/dl and HDL > 40 or 50 mg/dl in men or women,
respectively) [7]. Similarly, reports from other European
countries [8,9] and the United States [10] show that not
all eligible patients receive cholesterol-lowering therapy.
The reasons behind statin undertreatment are unclear.
Statins are available in generic form and they are afforda-
ble. However, while in Germany costs for reimbursement
are covered by health insurers, physicians' prescribing
habits are constrained by a pre-defined overall drug
budget. Professional bodies in Germany are reluctant rec-
ommending statin therapy for all diabetic patients (e. g.
[11]) despite unequivocal evidence of their efficacy from
numerous randomized trials and meta-analyses [12-14].
While there is an ongoing debate as to whether diabetes
should be considered a coronary heart disease (CHD)
equivalent [15], the National Cholesterol Education Pro-
gramme defined the status of diabetes mellitus already in
2004 as a CHD risk equivalent [16].
The main goal of the present study was to identify patient
characteristics predictive of who would receive a statin (or
not). For pragmatic reasons, we decided to stratify the
patients in bivariate analyses according to primary and
secondary prevention before constructing a multivariate
logistic regression model including the prevention status.
We used the DUTY diabetes registry [6,17] with > 50,000
patients from all over Germany.
Methods
Study design and subjects
The DUTY registry (Diabetes mellitus needs unrestricted
evaluation of patient data to yield treatment progress) is a
cross-sectional study in outpatients with type 2 diabetes.
The study protocol was approved by the Ethics Committee
of the Bavarian Chamber of Physicians. The study design
has been published elsewhere [18]. In short, between Feb-
ruary 2002 and November 2003 office-based physicians
in Germany were approached to participate in the study
and to recruit 20 consecutive diabetic patients. Reports of
59,075 patients from 3213 physicians were received. Of
these patients, 89.8% had type 2 diabetes, 5.7% type 1,
and in 4.5% the type of diabetes was not identified. For
the present evaluation, only patients with type 2 diabetes
were considered. Moreover, only data sets where patient
gender could be identified were considered. Thus, data of
51,640 patient data sets were analyzed.
Main outcome measure was receiving a statin prescrip-
tion. We investigated in bivariate analyses factors associ-
ated with statin prescription in subjects stratified
according to whether they had a history of CHD, stroke,
or peripheral arterial occlusive disease (secondary preven-
tion), and in subjects presumed free of atherosclerotic
complications (primary prevention).
Definition of parameters
Diabetes was defined by the treating physician. Hyperten-
sion was defined by the presence of antihypertensive drug
therapy or by a blood pressure reading of ≥ 140 mmHg
systolic or ≥ 90 mmHg diastolic. Lipoproteins, HbA1c,
and albumin in urine were determined with routine labo-
ratory methods. Microalbuminuria was defined as albu-
min excretion in urine ≥ 20 mg/l. Smoking status was
documented as self-reported current smoking, former
smoking, and never smoking. Glomerular filtration rate
was estimated using the Modification of Diet in Renal Dis-
ease formula [19].
In the primary prevention group, 5-year risk estimates for
the prediction of cardiovascular disease were calculated
using the equations developed with the data of the Swed-
ish National Diabetes Registry according to Cederholm et
al. [20]. The risk equation contains the following parame-
ters: age at onset of diabetes, duration of diabetes, HbA1c,
body mass index (BMI), systolic blood pressure, sex,
smoking status, and antihypertensive and lipid-lowering
medications.
Lipoprotein concentrations are an important determinant
of prescribing a statin. Since in a cross-sectional study
there are no baseline 'untreated' levels available, we mod-
elled baseline LDL cholesterol levels in the subjects receiv-
ing lipid-lowering drug therapy. The measured LDL levels
were corrected assuming a 15% reduction. This effect sizeCardiovascular Diabetology 2009, 8:25 http://www.cardiab.com/content/8/1/25
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was calculated based on the following assumptions: We
used the statins prescribed in Germany in 2002 and their
daily defined doses [21] and calculated their expected
LDL-lowering effect. Statin medication possession ratio
(i.e. the number of doses dispensed in relation to the dis-
pensing period) and adherence to treatment (i.e. doses
taken in relation to what was prescribed) were assumed to
be 50 to 75% and 50%, respectively, as previously
described [22,23].
Statistical methods
Continuous variables are given as mean values ± standard
deviations. Categorical variables are described as propor-
tions (percentage) and 95% confidence intervals were cal-
culated from binomial distributions. We stratified all
evaluations in our first model according to primary or sec-
ondary prevention. Of note, some of the patients had
more than one atherosclerotic disease entity (Figure 1).
We used bivariate analyses to examine frequency distribu-
tions and variability and we calculated odds ratios and P
values for the main outcome measure in a 1st model from
simple logistic regression analyses. In a 2nd model, we
multiple-adjusted for parameters that were identified in
the 1st model. Forward and backward stepwise logistic
regression using maximum likelihood-ratio statistics were
used for further support of variable selection. The full
model included sex, age, age at diagnosis of diabetes, BMI,
smoking status, established concomitant atherosclerotic
disease, hypertension, microalbuminuria, estimated
glomerular filtration rate, HbA1c, baseline LDL choles-
terol, HDL cholesterol, and triglycerides.
Because in 3 variables (age, age at diagnosis and BMI) in
bivariate analyses statin prescription was associated with
an inverted U-shape of the data (see Figure 2), we added
squared terms of these variables. Due to differential pre-
scription patterns seen in primary and secondary preven-
tion (see Table 1), we added the interaction terms
'sex*atherosclerotic disease', 'baseline LDL choles-
terol*atherosclerotic disease', and 'smoking sta-
tus*atherosclerotic disease'. Other interactions were
evaluated for inclusion but none was found to improve
the model. Missing data on atherosclerotic disease were
imputed as 'no known atherosclerotic disease'. Otherwise
no missing data imputations were performed. The ade-
quacy of the derived model equation was assessed by
standard goodness-of-fit procedures. Sensitivity analysis
of the model was performed by repeating the analyses
using prescription of all lipid-lowering drugs therapies (e.
g., fibrates) rather than the prescription of statins alone.
These results were similar and the data are not shown. We
used the Statistical Package for the Social Sciences Version
16.1.2 for all calculations (SPSS Inc., Munich, Germany).
All statistical tests were performed two-sided and a P-
value of < 0.05 was considered significant.
Results
Patient demographics, comorbidities, and complications
Patient demographics and the presence of individual cov-
ariates are shown in Table 2. There were 52.9% of the sub-
jects in primary prevention and 34.0% in secondary
prevention (in 13.1% the prevention status could not be
identified). In secondary prevention, 78.3% had CHD,
21.2% cerebrovascular disease, and 25.7% peripheral
artery disease. The prevalence of the different vascular dis-
ease entities is shown in Figure 1. More than 83% in pri-
mary and > 94% in secondary prevention had
hypertension. Albuminuria was present in 19.6% in pri-
mary and 39.1% in secondary prevention.
Overall, in primary prevention 12.6% of the patients
reached LDL cholesterol target levels of < 100 mg/dl and
in secondary prevention 16.3%. The proportion of pri-
mary prevention patients in various classes of 5-year esti-
mated risk can be seen in Table 2.
Statin treatment: bivariate analyses
Table 1 shows demographic and clinical characteristics in
patients with and without statin prescription. In primary
prevention 24% of the patients were on any type of lipid-
Prevalence of the different atherosclerotic disease entities  (small figures) and respective statin prescription frequencies  (large figures) for men (M) and women (F) Figure 1
Prevalence of the different atherosclerotic disease 
entities (small figures) and respective statin prescrip-
tion frequencies (large figures) for men (M) and 
women (F). Note that some patients had > 1 atheroscle-
rotic disease manifestation sites, so the numbers may add up 
to > 100%.
M 43 %  M 33 % 
M 42 % F 35 %  F 30 % 
F 40 %
Coronary
heart
disease
Cerebrovascular 
disease
Peripheral
arterial
occlusive
disease
M 49 %
F 37 %
M M 4 4 % %
F F 3 3 % %
M 29 %
F 29 %
M 49 % 
F 40 % 
M 36 %
F 31 %
M M 1 13 3 % %
F F 1 10 0 % %
M M 3 3 % %
F F 2 2 % %
M M 1 14 4 % %
F F 1 10 0 % %
M M 5 53 3 % %
F F 5 59 9 % %
M M 8 8 % %
F F 1 10 0 % %
M M 6 6 % %
F F 6 6 % %Cardiovascular Diabetology 2009, 8:25 http://www.cardiab.com/content/8/1/25
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lowering drug therapy and 18.5% were receiving a statin,
while in secondary prevention 46% were receiving any
type of lipid-lowering drug therapy and 38% a statin.
Fibrates were prescribed in 5.8% and 7.9% of patients,
respectively. The respective statin prescription frequencies
according to atherosclerotic disease manifestation site are
depicted in Figure 1. Statin prescription was higher in men
than in women in general and higher in patients with
CHD than in patients with cerebrovascular and peripheral
arterial disease. Highest prescription frequencies were
observed when CHD and peripheral disease were concur-
rently present.
Table 3 shows bivariate analyses of factors determining
statin prescription. Results are expressed in percent of the
respective group receiving a statin. Odds ratios for receiv-
ing a statin and confidence intervals for binomial distri-
butions can be obtained from the online Additional file 1.
In unadjusted analyses, women received less frequently
statin prescriptions than men. In both, primary and sec-
ondary prevention, statin prescription was highest in the
6th and 7th decade of life but declined at higher age. The
association with age showed an inverted U-shaped curve
(nadir, 66 years; Figure 2A). Similarly, in primary preven-
tion the odds of receiving a statin were lower at younger
and higher age at first diagnosis of diabetes (nadir, 56
years), while in secondary prevention the highest prescrip-
tion rates were seen in patients diagnosed at age < 45 years
(Figure 2B). Diabetes duration had an influence on statin
prescription in bivariate analyses (OR per year 1.018, 95%
CI 1.015 to 1.021, P < 0.0001), but not in multivariate
analyses. A body mass index of > 35 kg/m2 but also BMI
values < 25 kg/m2 decreased the odds of statin prescrip-
tion when compared with moderate overweight (nadir,
BMI 32 kg/m2), both in primary and secondary preven-
tion (Figure 2C). Former smokers had higher odds of
Table 1: Demographic and clinical characteristics in patients with and without statin prescription.*
Characteristic Statin prescription No statin prescription
Number, (%) 13,150 (25.5%) 38,490 (74.5%)
Men (%) 27.6 72.4
Women (%) 23.4 76.6
Age (years) 65.6 ± 9.5 65.1 ± 11.3
Age at diagnosis of diabetes (years) 58.3 ± 10.2 58.5 ± 11.2
Diabetes duration (years) 7.3 ± 6.4 6.6 ± 6.1
Body mass index (kg/m2) 28.9 ± 4.4 28.9 ± 4.9
Smoking status
Never smoker (%) 23.6 76.4
Former smoker (%) 31.5 68.5
Current smoker (%) 24.4 75.6
Hypertension (%) 86.4 13.6
Systolic blood pressure (mmHg) 143 ± 17 143 ± 18
Diastolic blood pressure (mmHg) 83 ± 10 83 ± 10
Microalbuminuria (%) 42.3 57.7
Creatinine (mg/dl) 1.35 ± 2.51 1.31 ± 2.45
Estimated glomerular filtration rate (ml/min) 74 ± 36 76 ± 37
HbA1c (%) 7.3 ± 1.3 7.3 ± 1.3
Fasting plasma glucose (mg/dl) 147 ± 46 148 ± 48
Lipoprotein concentrations
Total cholesterol (mg/dl) 221 ± 53 226 ± 50
LDL cholesterol (mg/dl) 131 ± 40 138 ± 38
HDL cholesterol (mg/dl) 48 ± 13 49 ± 14
Triglycerides (mg/dl) 226 ± 260 218 ± 313
Estimated 5-year cardiovascular risk (primary prevention) 18.3 ± 10.6 14.5 ± 10.1
Atherosclerotic complications
Coronary heart disease (%) 43.5 56.5
Cerebrovascular disease (%) 11.0 89.0
Peripheral art. occlusive dis. (%) 15.5 84.5
*Data are means ± SD or proportions (in %).Cardiovascular Diabetology 2009, 8:25 http://www.cardiab.com/content/8/1/25
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receiving a statin when compared with current smokers
and never smokers in secondary prevention. In primary
prevention, prescription rates were comparable among
never smokers, former smokers and current smokers. The
subjects with hypertension had almost doubled odds of
receiving a statin (Table 3 and Additional file 1). When
albuminuria was present, the odds of receiving a statin
increased in comparison to patients with no microalbu-
minuria (Table 3 and Additional file 1). Glycemic control,
as reflected by HbA1c, had no influence and was not
included in the final model. Estimated glomerular filtra-
tion rate was negatively associated with statin prescription
(OR per ml/min 0.998, 95% CI 0.997 to 0.999, P  <
0.0001) in bivariate but not in multivariate analyses. Trig-
lycerides and HDL cholesterol concentrations were not
associated with statin prescription.
In primary prevention, there was a continuous increase in
prescription frequency from the lowest (< 5%) to the
highest (> 30%) 5-year estimated risk groups. These data
are depicted separately for men and women in Figure 3.
Table 4 shows the results when simulating baseline LDL
level conditions. Prescription rates were highest in the
groups of LDL cholesterol ≥160 mg/dl in both, primary
and secondary prevention, but odds ratios were more pro-
nounced in primary prevention.
Statin treatment: multivariate logistic regression analysis
The parameters with the strongest association in bivariate
analyses, namely presence of atherosclerotic disease and
presence of hypertension were included in the model
from the beginning. The best fit was achieved using the
following covariates: age, age at first diagnosis of diabetes,
smoking status, albuminuria, baseline LDL cholesterol,
and BMI. Furthermore, the interaction terms 'sex*athero-
sclerotic disease', 'baseline LDL*atherosclerotic disease'
and 'smoking status*atherosclerotic disease' were all
highly significant. All parameters were independently
associated with statin prescription, except for sex when
the interaction term was used. The respective odds ratios,
confidence intervals and P-values are shown in Table 5.
Atherosclerotic disease, hypertension, former smoking,
high LDL cholesterol, and albuminuria increased the odds
for statin prescription, while it was decreased in higher or
lower age, higher or lower age at diagnosis of diabetes,
and higher or lower BMI. We found some significant inter-
actions: the significant interaction term between athero-
sclerotic disease and sex indicated that women in
secondary but not in primary prevention had lesser odds
of receiving a statin. With this interaction term in place,
sex by itself was not significant. The significant interaction
between atherosclerotic disease and baseline LDL choles-
terol indicated that high cholesterol was a stronger predic-
tor of statin prescription in secondary than in primary
prevention. The significant interaction between athero-
sclerotic disease and smoking status indicated that the
increased odds of receiving a statin in former smokers
were most pronounced in secondary prevention.
Using this model (total N = 37,110 patients), correct pre-
diction of receiving a statin was 51% (sensitivity) and cor-
rect prediction of not receiving a statin was 77%
(specificity). The overall proportion of correct prediction
of our model was 70%.
Discussion
Our results demonstrate that the presence of hyperten-
sion, high baseline LDL cholesterol, and microalbuminu-
ria as well as a former smoking status, are positive
predictors for receiving statin prescriptions. The most
important predicting factor is the patient's cardiovascular
risk. On the other hand, older or younger age, older or
younger age at first diagnosis of diabetes, and higher or
Unadjusted statin prescription frequencies according to age  (A), age at diagnosis of diabetes (B), and body mass index (C) Figure 2
Unadjusted statin prescription frequencies according 
to age (A), age at diagnosis of diabetes (B), and body 
mass index (C). Primary prevention data are shown on the 
left and secondary prevention on the right side. Data are 
proportions (%) and 95% confidence intervals for binomial 
distributions.
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Table 2: Subject demographics for patients with type 2 diabetes (n = 51,640) in primary or secondary prevention*.
Characteristic Primary prevention Secondary prevention Prevention status unknown
Number, (%) 27,322 (52.9%) 17,571 (34.0%) 6,747 (13.1%)
Male sex (%) 45.5% 54.2% 46.7%
Age (years) 62.9 ± 10.9 69.3 ± 9.5 64.0 ± 10.8
Age at diagnosis of diabetes (years) 57.1 ± 10.9 61.0 ± 10.5 57.6 ± 11.0
Diabetes duration (years) 5.8 ± 5.7 8.3 ± 6.8 6.3 ± 5.9
Body mass index 29.1 ± 4.9 28.5 ± 4.4 29.1 ± 4.8
Smoking status (%)
Never smoker 64.8% 54.2% 52.5%
Former smoker 17.3% 27.7% 17.8%
Current smoker 17.6% 15.0% 9.0%
Hypertension (%) 83.3% 94.8% 84.8%
Microalbuminuria (>20 mg/l) 27.8% 34.9% 31.1%
HbA1c (%)
<6.5% 27.3% 23.8% 26.1%
≥6.5% and <7.5% 37.0% 34.6% 35.2%
≥7.5% and <8.5% 21.1% 24.4% 22.8%
≥8.5% 13.9% 16.3% 14.5%
Lipoprotein concentrations (mg/dl)
Total cholesterol
<200 27.8% 32.4% 30.5%
≥200 and <240 35.4% 32.0% 33.2%
≥240 34.7% 32.2% 35.0%
LDL cholesterol
<100 12.6% 16.3% 14.1%
≥100 and <130 25.0% 24.2% 24.1%
≥130 and <160 26.9% 23.6% 24.6%
≥160 22.6% 21.4% 21.8%
HDL cholesterol
<40 (M) or <50 (F) 36.2% 39.3% 36.0%
≥40 (M) or ≥50 (F) 55.8% 53.6% 55.2%
Triglycerides
<150 30.5% 29.0% 28.9%
≥150 and <400 50.1% 51.7% 50.2%
≥400 4.5% 4.9% 3.9%
On lipid-lowering medication (%)
Any 24.0% 45.8% 31.6%
Statins 18.5% 38.1% 25.1%
Fibrates 5.8% 7.9% 7.2%
Other 0.11% 0.14% 0.10%
Atherosclerotic risk or disease, 
respectively
5-Year atherosclerotic disease risk 
(%)
Presence of atherosclerotic disease 
(%)
unknown
<5%: 11.0% Coronary heart disease: 78.3%
≥5% and <10%: 21.9% Cerebrovascular disease: 21.2%
≥10% and <15%: 19.2% Periph. art. occlussive dis.: 25.7%
≥15% and <20%: 14.0%
≥20% and <25%: 9.3%
≥25% and <30%: 5.7%
≥30%: 8.1%
In 6747 patients (13.1%) the prevention status was unknown
*Data are means ± SD or proportions (in %).Cardiovascular Diabetology 2009, 8:25 http://www.cardiab.com/content/8/1/25
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Table 3: Proportions of statin prescription in bivariate analysis.
Characteristic Primary prevention Secondary prevention
Percent statin use Percent statin use
Number n = 27,322
18.5%
n = 17,571
38.1%
Sex
Male 18.5% 41.3%
Female 18.5% 34.4%
Age (years)
<40 11.7% 37.8%
≥40 and <50 14.7% 43.3%
≥50 and <60 18.9% 43.3%
≥60 and <70 21.2% 43.3%
≥70 and <80 17.9% 36.8%
≥80 11.7% 21.9%
Age at diagnosis of diabetes (years)
<45 16.6% 44.8%
≥45 and <55 19.0% 42.1%
≥55 and <65 20.5% 41.0%
≥65 16.4% 31.8%
Diabetes duration (years)
<1 11.4% 37.9%
≥1 and <5 19.3% 39.2%
≥5 and <10 18.9% 38.0%
≥10 20.2% 37.1%
Body mass index (kg/m2)
<25 16.5% 33.0%
≥25 and <30 19.3% 39.1%
≥30 and <35 19.1% 40.7%
≥35 16.9% 37.6%
Smoking status
Never smoker 18.1% 35.2%
Former smoker 20.1% 44.8%
Current smoker 18.5% 36.0%
Hypertension
no 11.7% 22.9%
yes 19.9% 39.0%
HbA1c (%)
<6.5 17.8% 36.9%
≥6.5 and <7.5 19.2% 39.8%
≥7.5 and <8.5 18.8% 36.7%
≥8.5 17.6% 38.5%
Albuminuria
No albuminuria 17.4% 37.4%
Albuminuria
(≥20 mg/l)
19.0% 39.1%
Lipoprotein concentrations (mg/dl)
Total cholesterol
<200 19.9% 47.2%
≥200 and <240 16.2% 34.8%
≥240 19.7% 32.6%Cardiovascular Diabetology 2009, 8:25 http://www.cardiab.com/content/8/1/25
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lower BMI are decreasing the odds of receiving a statin.
Since patients with diabetes have a substantially increased
risk of atherosclerotic vascular disease, identification of
treatment for the prevention of vascular events is a public-
health priority. The NCEP already in 2004 recommended
LDL-C goals of < 100 mg/dl in high-risk patients, includ-
ing patients with diabetes and an LDL-C of < 70 mg/dl as
an option for very high risk patients [16]. However, statin
prescription to every single diabetes patient is a controver-
sially discussed issue. According to the recently published
joint guidelines of the European Society of Cardiology
(ESC) and the European Association for the Study of Dia-
betes (EASD) the goals of therapy proposed for diabetic
patients in primary prevention are similar to those for
non-diabetic patients with symptomatic CVD (total cho-
lesterol < 174 mg/dl, LDL-C < 97 mg/dl) [3]. The decision
whether statin therapy should be started in patients whose
LDL-C is already < 100 mg/dl is left to individual judge-
ment. In the Collaborative Atorvastatin Diabetes Study
(CARDS), statins for primary prevention were investi-
gated in patients with type 2 diabetes without high LDL-C
and a significant reduction in major cardiovascular events,
including stroke, was found [12]. Further studies con-
firmed that statins provide a wide range of cardiovascular
risk benefit in patients with diabetes, independently of
their baseline LDL cholesterol [24]. A meta-analysis in
non-diabetic and diabetic patients suggested that diabetic
patients, after adjustment for baseline characteristics, ben-
efit even more than non-diabetes patients from lipid-low-
ering therapy in both primary and secondary prevention
[14]. Overall, the evidence suggests that most diabetic
patients should receive a statin.
The present study found that only 25% of patients with
diabetes receive statin prescriptions. Prescription frequen-
cies are higher in secondary prevention. Interestingly, in
primary prevention, the odds of receiving a statin
increased in parallel with the 5-year estimated risk for car-
diovascular disease, indicating that prescription decisions
are, at least in part, based on risk assessment. Previous
studies in non-diabetic populations have shown that
patients receiving statins are more likely to have severe
cardiovascular comorbidities and to be elderly [25], but a
remaining substantive underuse in high-risk patients has
also been described [26]. Another interesting finding in
our study was that both, the presence of hypertension and
albuminuria were associated with increased odds of statin
prescription, suggesting that both disease entities are
being correctly perceived as predictors of CVD [27]. Sur-
prisingly former smokers had higher odds of receiving a
statin than never smokers or current smokers in secondary
prevention. It could be postulated that former smokers (i)
LDL cholesterol
<100 23.8% 54.9%
≥100 and <130 19.7% 42.0%
≥130 and <160 16.9% 32.0%
≥160 19.0% 30.9%
HDL cholesterol
<40 (M) or <50 (F) 19.9% 38.2%
≥40 (M) or ≥50 (F) 19.1 39.9%
Triglycerides
<150 9.8% 37.3%
≥150 and <400 20.0% 38.9%
≥400 22.9% 45.4%
Estimated 5-year cardiovascular risk (%)
<5 6.6%
≥5 and <10 13.9%
≥10 and <15 19.7%
≥15 and <20 23.4%
≥20 and <25 23.9%
≥25 and <30 26.9%
≥30 26.9%
Atherosclerotic complications
Coronary heart disease 40.1%
Cerebrovascular disease 37.3%
Peripheral arterial occlusive disease 38.0%
Subjects were stratified according to primary or secondary prevention and groups were analyzed separately. Confidence intervals and odds ratios 
for receiving a statin can be obtained from Additional file 1.
Table 3: Proportions of statin prescription in bivariate analysis. (Continued)Cardiovascular Diabetology 2009, 8:25 http://www.cardiab.com/content/8/1/25
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are considered to be still at a higher risk than never smok-
ers and (ii) are 'rewarded', consciously or subconsciously,
by their physicians for quitting smoking.
We identified three major parameters that were signifi-
cantly associated with decreased statin prescription:
young or old age, younger or older age at first diagnosis of
diabetes, and subjects with higher or lower BMI values.
Our findings that the elderly receive less treatment are in
agreement with those of Teeling at al. [28], who showed a
decreased probability of receiving a statin in patients age
65 and older, and to those of Ko et al. [29], who showed
that in the elderly prescription of statins diminished pro-
gressively as CVD risk increased ("treatment-risk para-
dox"). In another study it was shown that prescription
among patients > 74 years was 40% lower than in younger
patients [30]. Interestingly, an inverted U-shaped curve
association between age and statin prescription was
described before [31]. Not only have several studies
shown that elderly patients benefit from statin treatment
if they have risk factors for vascular disease or established
vascular disease [14,32], there is increasing evidence that
treatment initiation early in life before the atherosclerotic
process has become advanced may be beneficial [33]. The
reasons behind fewer prescriptions at higher age may be
concerns about treatment complications or shifting prior-
ities for drug treatment from outcome-influencing drugs
towards symptomatic treatments in multimorbid
patients. Since age is the strongest component of the over-
all risk score and actual prescription decreases with higher
age, the contribution of other risk factors to the odds of
receiving statin prescriptions is even greater at higher age.
Our results of increasing statin use with increasing BMI
are in accordance to findings of Agalliu et al. [34] and
Neutel et al. [26]. However, these studies did not address
individuals with BMI > 35 kg/m2. Our finding of
decreased odds of statin prescription above a higher BMI
and in normal weight individuals might reflect the physi-
cians' belief that the former will not benefit from such
treatment and the latter do not really need it.
We have previously shown that female sex is associated
with statin undertreatment in patients with diabetes, espe-
cially in secondary prevention [17]. In the present study
we confirm these results which are also in agreement to
those of other investigators [31,35,36].
For estimating cardiovascular risk in primary prevention
we used the newly developed risk equations from Sweden
that were specifically designed and prospectively vali-
dated in patients with type 2 diabetes [20]. Other risk cal-
culators have been criticized for not providing reliable
estimates for such patients [37]. A further advantage of
this risk calculator was that in the DUTY registry in more
than 89% of the subjects all necessary parameters were
available. Our finding showing an increase in the odds of
receiving statin prescriptions in parallel to the increase in
the overall 5-year estimated risk is reassuring, since it
implies physicians' awareness of the concept of cardiovas-
cular risk or individual risk estimation. The reasons for
higher prescription rates in women in comparison to men
in the mid-risk range (Figure 3) remain unclear.
The possible reasons behind the overall low prescription
rates have to be addressed. Drug costs may play an impor-
tant role in the wide underuse of statins. A study analyzing
treatment costs at the time of data sampling of the DUTY
registry found that costs for statins were higher than those
for all other cardiovascular drugs that were prescribed to
patients with type 2 diabetes together and the prescription
Unadjusted statin prescription frequencies in men (A) and  women (B) according to the estimated 5-year cardiovascular  event risk Figure 3
Unadjusted statin prescription frequencies in men 
(A) and women (B) according to the estimated 5-
year cardiovascular event risk. Data are proportions (%) 
and 95% confidence intervals for binomial distributions.
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rates for statins had been increasing 8-fold in the 10-year
period before [23]. However, there is strong evidence to
support that the statin-induced reduction of cardiovascu-
lar events in diabetic patients, both in primary and sec-
ondary prevention, is cost-effective [38]. More
importantly, reluctant national recommendations, e. g. of
disease management programmes, may play a major role
[11].
Limitations
Our study has several limitations. First, the list of the pos-
sible covariates examined is not complete. Statin prescrip-
tion might depend on other factors not documented in
the current registry. For example, the status of the patient's
health insurance (private or statutory health insurance) as
well as the socio-economic level of the subjects [39] may
play a role. Second, physicians reported to the best of their
knowledge of statin prescription; hence the data do not
account for medication dispensing  and  adherence  rates.
Third, we don't have information about which statin at
which dose was used. It is known that many statins are
prescribed at doses lower than those shown to be effective
in randomized trials [40]. And last, the degree of statin-
induced lipid-lowering was calculated, not measured. The
calculation of a mean lipid-lowering effect of 15% is only
an approximate indicator but simulations with different
effect sizes revealed similar results (data not shown).
To our knowledge this is the first study addressing the var-
ious predictors of statin prescription in patients with type
2 diabetes. The strength of our findings lies in the hetero-
geneity and the size of the population investigated and the
use of multivariate analyses. By indentifying independent
parameters that influence medical decision making in
issues of vital importance, such as prescription of statins
to patients with diabetes, these results represent a substan-
tial opportunity for improvement in diabetes quality of
care. The study contributes to understanding which
Table 5: Results of multivariate logistic regression analysis
Covariate Odds ratio 95% Confidence interval P-value
Atherosclerotic disease 7.27 5.75 to 9.20 <0.0001
Hypertension 1.87 1.70 to 2.07 <0.0001
Smoking 0.08
Former smokera 1.16 1.03 to 1.31 0.014
Current smokera 1.03 0.93 to 1.31 0.58
Albuminuria (albumin ≥20 mg/dl) 1.06 1.003 to 1.16 0.037
Baseline LDL cholesterolb 1.11 1.06 to 1.16 <0.0001
Age at first diagnosis of diabetesc 0.93 0.90 to 0.96 <0.0001
Aged 0.86 0.82 to 0.90 <0.0001
Body mass indexe 0.93 0.89 to 0.97 <0.0001
aIn comparison to never smokers
bOdds ratio for an increase of 10 mg/dl. For details for modelling baseline LDL levels see text
cOdds ratio for an increase or a decrease of 10 years from the nadir, 56 years
dOdds ratio for an increase or a decrease of 10 years from the nadir, 66 years
eOdds ratio for an increase or a decrease of 5 kg/m2 years from the nadir, 31.6 kg/m2
Table 4: Baseline LDL cholesterol levels modelled as 'untreated' (see text for methods)
LDL cholesterol (mg/dl) Primary prevention Secondary prevention
Percent statin use Odds ratio (95% CI) P-value Percent statin use (%) Odds ratio (95% CI) P-value
<100 12.6%
(11.4 to 13.9)
referent 39.0%
(36.9 to 41.2)
referent
≥100 and <130 14.8%
(14.0 to 15.7)
1.20
(1.06 to 1.37)
0.005 38.2%
(36.6 to 39.7)
0.97
(0.87 to 1.08)
0.54
≥130 and <160 16.2%
(15.4 to 17.1)
1.34
(1.18 to 1.52)
<0.0001 34.4%
(32.9 to 35.8)
0.82
(0.74 to 0.92)
0.0004
≥160 28.5%
(27.5 to 29.5)
2.76
(2.45 to 3.11)
<0.0001 43.3%
(41.9 to 44.7)
1.20
(1.08 to 1.33)
0.0009
*Proportions are described as percent and 95% confidence intervals for binomial distributions. Odds ratios with 95% confidence intervals were 
estimated by logistic regression analysis without adjustments.Cardiovascular Diabetology 2009, 8:25 http://www.cardiab.com/content/8/1/25
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parameters determine statin prescription but further stud-
ies are needed to investigate the reasons for withholding
this drug therapy.
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